Litcius/Paper detail

Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: Methodology and correlation with cardiac functional parameters

Satoru Watanabe, Kenichi Nakajima, Hiroshi Wakabayashi, Hiroto Yoneyama, Shohei Yoshida, Junji Komatsu, Takahiro Konishi, Anri Inaki, Seigo Kinuya

2021Journal of Nuclear Cardiology19 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Tc-PYP) SPECT/CT is a useful method for assessing transthyretin cardiac amyloidosis (ATTR-CA). We investigated the methodology and assessed its relationship with conventional parameters. METHODS AND RESULTS: Tc-PYP SPECT/CT scans of 25 patients who underwent endomyocardial biopsy and/or gene testing. Fourteen (56%) patients were diagnosed with ATTR-CA. SPECT/CT images were acquired at 3 hours after injection. Total volumes of the myocardial regions where uptakes were > 1.2 and 1.4 × aortic blood pool SUVmax were evaluated and defined as cardiac pyrophosphate volume (CPV1.2 and CPV1.4). The heart-to-contralateral lung (H/CL) ratio and myocardial SUVmax were also calculated. CPV1.2 achieved the highest sensitivity and specificity in diagnosing ATTR-CA. In patients diagnosed with ATTR-CA (n = 14), CPV1.2 negatively correlated with left ventricular ejection fraction and positively correlated with left ventricular posterior wall thickness and QRS duration. The correlation was stronger in CPV1.2 than in the H/CL ratio and SUVmax. CONCLUSION: Tc-PYP SPECT/CT may be superior to the H/CL ratio and SUVmax in assessing the disease burden of ATTR-CA. Larger studies are warranted to clarify whether volumetric measurement can assess prognosis and disease progression.

Topics & Concepts

MedicineCardiac amyloidosisNuclear medicineEjection fractionTransthyretinPyrophosphateRadiologyAmyloidosisInternal medicineHeart failureCardiologyBiochemistryEnzymeChemistryAmyloidosis: Diagnosis, Treatment, OutcomesParathyroid Disorders and TreatmentsDermatological and Skeletal Disorders